- Home
- CTNM vs CDRO Comparison
CTNM vs CDRO Comparison
Compare CTNM & CDRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNM | CDRO |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | Luxembourg |
| Employees | N/A | 369 |
| Industry | | Services-Misc. Amusement & Recreation |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.7M | 455.2M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CTNM | CDRO |
|---|---|---|
| Price | $12.58 | $10.01 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $19.00 | $9.00 |
| AVG Volume (30 Days) | ★ 460.7K | 30.2K |
| Earning Date | 05-13-2026 | 02-28-2023 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.31 |
| Revenue Next Year | N/A | $6.75 |
| P/E Ratio | ★ N/A | $305.95 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.60 | $5.18 |
| 52 Week High | $17.79 | $10.26 |
Technical Indicators
Market Signals| Indicator | CTNM | CDRO |
|---|---|---|
| Relative Strength Index (RSI) | 32.81 | 64.92 |
| Support Level | $11.73 | $8.53 |
| Resistance Level | $13.54 | $10.22 |
| Average True Range (ATR) | 0.90 | 0.42 |
| MACD | -0.29 | 0.07 |
| Stochastic Oscillator | 23.60 | 93.53 |
Price Performance
Historical ComparisonAbout CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
About CDRO Codere Online Luxembourg S.A.
Codere Online Luxembourg SA is an international online casino gaming and online sports betting group focused on providing its customers with a safe and enjoyable online gaming experience. It currently operates in Spain, Mexico, Colombia, and Other countries, where it offers its users the ability to play online casino games and bet on sports events. Online casino offerings include the full portfolio of games typically available in land-based casinos, gaming halls, and gambling establishments, such as slot machines, table games, and bingo. Online sports betting involves a user placing a wager on an event at some fixed odds determined by Codere Online. The company derives maximum revenue from Mexico.